Sapu Nano, a subsidiary of Oncotelic Therapeutics, will present its Deciparticle platform and clinical pipeline at BIO‑Europe Spring 2026 on March 25, 2026, following an announcement made on March 24.
The Deciparticle platform is a proprietary nanotechnology that encapsulates hydrophobic drugs into uniform, sub‑20 nm nanoparticles for intravenous administration. The technology improves systemic exposure, reduces gastrointestinal deposition, and enhances tumor penetration, and has successfully formulated more than 100 hydrophobic drugs to date.
Lead candidates Sapu003 (everolimus for injection) and Sapu006 (docetaxel for injection) are entering Phase 1 trials. Sapu003 has received approval for human trials in Australia, and the platform aims to convert cytostatic agents into cytotoxic therapies.
Oncotelic, formerly Mateon Therapeutics, focuses on oncology, especially rare pediatric cancers. The BIO‑Europe presentation positions Sapu Nano as a leading nanomedicine developer and could attract strategic partnerships, signaling progress from platform development to clinical translation.
The event underscores Sapu Nano’s move toward commercialization and may enhance investor perception of its technology, although no immediate market reaction data are available.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.